Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Mycoses ; 60(10): 626-633, 2017 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-28660636

RESUMO

Pneumocystis jirovecii is the causative agent of Pneumocystis pneumonia (PcP), a common and often life-threatening opportunistic infection in HIV-infected patients. However, non-HIV, immunocompromised patients are at risk of PcP as well, whereas the mortality appears to be higher among these patients. Pneumocystis co-infections with other microorganisms are less frequent and only sparse reports of combined PcP and invasive pulmonary fungal infections exist in the literature, especially in the non-HIV patients. Two cases of pulmonary co-infections by P. jirovecii and Aspergillus fumigatus are presented. Both patients were non-HIV infected, the first one was suffering from crescentic IgA nephropathy under immunosuppressive treatment and the second from resistant non-Hodgkin lymphoma under chemotherapy. Both patients were treated with intravenous trimethoprim/sulphamethoxazole (TMP/SMX) combined with voriconazole. The first patient showed gradual clinical improvement while the outcome for the second patient was unfavourable. In addition, a literature review of the previous published cases of co-infection by P. jirovecii and other fungi in non-HIV patients was performed. Our target was to provide comprehensive information on this kind of infections, highlighting the importance of clinical suspicion.


Assuntos
Aspergillus fumigatus/fisiologia , Coinfecção , Pulmão/microbiologia , Pneumocystis carinii/fisiologia , Pneumonia por Pneumocystis/microbiologia , Aspergilose Pulmonar/complicações , Infecções Oportunistas Relacionadas com a AIDS/microbiologia , Adulto , Idoso de 80 Anos ou mais , Coinfecção/tratamento farmacológico , Feminino , Humanos , Hospedeiro Imunocomprometido , Imunossupressores/uso terapêutico , Infecções Fúngicas Invasivas/tratamento farmacológico , Infecções Fúngicas Invasivas/microbiologia , Masculino , Pessoa de Meia-Idade , Pneumonia por Pneumocystis/tratamento farmacológico , Pneumonia por Pneumocystis/mortalidade , Aspergilose Pulmonar/tratamento farmacológico , Aspergilose Pulmonar/microbiologia , Aspergilose Pulmonar/mortalidade , Estudos Retrospectivos , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...